I just sent an email to several staff members of "Endpoints News" a pharma news journal:

I'd like to call to your attention the recent press release of IPIX, Innovation Pharmaceuticals, regarding their deal with the Italian pharma co., Alphasigma:
INNOVATION PHARMACEUTICALS ANNOUNCES LICENSE AGREEMENT WITH ALFASIGMA S.P.A. FOR THE DEVELOPMENT AND COMMERCIALIZATION OF BRILACIDIN IN ULCERATIVE PROCTITIS/ULCERATIVE PROCTOSIGMOIDITIS
Brilacidin is been successful in several studies. I hope you will investigate and report about this promising development.
Disclosure: I am a shareholder of IPIX.
Thanks,
gh